Literature DB >> 20373871

Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Jiao Zhang1, Yan-Hua Chen, Qun Lu.   

Abstract

Carcinogenesis is the uncontrolled growth of cells gaining the potential to invade and disrupt vital tissue functions. This malignant process includes the occurrence of 'unwanted' gene mutations that induce the transformation of normal cells, for example, by overactivation of pro-oncogenic pathways and inactivation of tumor-suppressive or anti-oncogenic pathways. It is now recognized that the number of major signaling pathways that control oncogenesis is not unlimited; therefore, suppressing these pathways can conceivably lead to a cancer cure. However, the clinical application of cancer intervention has not matched up to scientific expectations. Increasing numbers of studies have revealed that many oncogenic-signaling elements show double faces, in which they can promote or suppress cancer pathogenesis depending on tissue type, cancer stage, gene dosage and their interaction with other players in carcinogenesis. This complexity of oncogenic signaling poses challenges to traditional cancer therapy and calls for considerable caution when designing an anticancer drug strategy. We propose future oncology interventions with the concept of integrative cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373871      PMCID: PMC2886915          DOI: 10.2217/fon.10.15

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  269 in total

1.  Identification and localization of a neurally expressed member of the plakoglobin/armadillo multigene family.

Authors:  R Paffenholz; W W Franke
Journal:  Differentiation       Date:  1997-08       Impact factor: 3.880

2.  Oncogene regulation of tumor suppressor genes in tumorigenesis.

Authors:  Jimmy Sung; Joel Turner; Susan McCarthy; Steve Enkemann; Chan Gong Li; Perally Yan; Timothy Huang; Timothy J Yeatman
Journal:  Carcinogenesis       Date:  2004-10-21       Impact factor: 4.944

3.  [Interaction of E2F/Rb family members with factor binding to co-repressor element on B-myb and E2F1 promoters].

Authors:  Y Nakajima
Journal:  Kokubyo Gakkai Zasshi       Date:  1998-06

4.  Role of transforming growth factor-beta signaling in cancer.

Authors:  M P de Caestecker; E Piek; A B Roberts
Journal:  J Natl Cancer Inst       Date:  2000-09-06       Impact factor: 13.506

5.  Mutation of the PIK3CA gene in ovarian and breast cancer.

Authors:  Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

6.  Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.

Authors:  Andrea D Basso; David B Solit; Pamela N Munster; Neal Rosen
Journal:  Oncogene       Date:  2002-02-14       Impact factor: 9.867

7.  Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion.

Authors:  John N Hutchinson; Jing Jin; Robert D Cardiff; Jim R Woodgett; William J Muller
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

8.  PIK3CA mutation associates with improved outcome in breast cancer.

Authors:  Kevin Kalinsky; Lindsay M Jacks; Adriana Heguy; Sujata Patil; Marija Drobnjak; Umeshkumar K Bhanot; Cyrus V Hedvat; Tiffany A Traina; David Solit; William Gerald; Mary Ellen Moynahan
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

Review 9.  Structures and functions of the tumor suppressor p53.

Authors:  J Milner
Journal:  Pathol Biol (Paris)       Date:  1997-12

10.  Targeted deletion of the TGF-beta 1 gene causes rapid progression to squamous cell carcinoma.

Authors:  A B Glick; M M Lee; N Darwiche; A B Kulkarni; S Karlsson; S H Yuspa
Journal:  Genes Dev       Date:  1994-10-15       Impact factor: 11.361

View more
  7 in total

1.  Intratumor δ-catenin heterogeneity driven by genomic rearrangement dictates growth factor dependent prostate cancer progression.

Authors:  Mingchuan Li; Jongdee Nopparat; Byron J Aguilar; Yan-Hua Chen; Jiao Zhang; Jie Du; Xin Ai; Yong Luo; Yongguang Jiang; Christi Boykin; Qun Lu
Journal:  Oncogene       Date:  2020-04-20       Impact factor: 9.867

Review 2.  Comprehending the crosstalk between Notch, Wnt and Hedgehog signaling pathways in oral squamous cell carcinoma - clinical implications.

Authors:  Anjali P Patni; M K Harishankar; Joel P Joseph; Bhuvanadas Sreeshma; Rama Jayaraj; Arikketh Devi
Journal:  Cell Oncol (Dordr)       Date:  2021-03-11       Impact factor: 6.730

3.  Uncovering molecular events associated with the chemosuppressive effects of flaxseed: a microarray analysis of the laying hen model of ovarian cancer.

Authors:  Karen H Hales; Sheree C Speckman; Nawneet K Kurrey; Dale B Hales
Journal:  BMC Genomics       Date:  2014-08-24       Impact factor: 3.969

4.  δ-Catenin, a Wnt/β-catenin modulator, reveals inducible mutagenesis promoting cancer cell survival adaptation and metabolic reprogramming.

Authors:  J Nopparat; J Zhang; J-P Lu; Y-H Chen; D Zheng; P D Neufer; J M Fan; H Hong; C Boykin; Q Lu
Journal:  Oncogene       Date:  2014-04-14       Impact factor: 9.867

5.  Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.

Authors:  Min Shi; Weizhen Huang; Li Lin; Dayong Zheng; Qiang Zuo; Lin Wang; Nina Wang; Yajun Wu; Yulin Liao; Wangjun Liao
Journal:  PLoS One       Date:  2012-08-23       Impact factor: 3.240

6.  The miR-106a~363Xpcl1 miRNA cluster induces murine T cell lymphoma despite transcriptional activation of the p27Kip1 cell cycle inhibitor.

Authors:  Daniel A Kuppers; Thomas M Schmitt; Harry C Hwang; Lavanya Samraj; Bruce E Clurman; Matthew L Fero
Journal:  Oncotarget       Date:  2017-04-07

7.  A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer.

Authors:  Azeez A Fatai; Junaid Gamieldien
Journal:  BMC Cancer       Date:  2018-04-03       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.